IAVI and Partners Initiate AIDS Vaccine Trial in Africa

IAVI announced the start of a multi-center Phase I trial in Africa to evaluate the safety and immunogenicity of a preventive AIDS vaccine candidate made up of two components. The trial, named B002, is the first to test these components used in combination, with the aim of producing broader and stronger immune responses than can be achieved with either component alone. One component of the vaccine combination is based on a recombinant protein. The other is constructed using a virus other than HIV as a vector to transport man-made versions of HIV genes into the body. The trial is sponsored by IAVI and will be conducted in partnership with GlaxoSmithKline (GSK), the Kenya AIDS Vaccine Initiative (KAVI) and as many as three other partners in Africa pending approvals.  For more information, visit

Global HIV Vaccine Enterprise, 64 Beaver Street, # 352, New York, NY 10004 | +1 212-461-3692 or toll free at +1-866-966-4483
All Content ©2005 - 2013 Global HIV Vaccine Enterprise   |   Terms of Use   |   Privacy Policy   |   Log In / My Account